Who we are

Understanding the complexity of the immune response to tumors and identifying new biomarkers to predict patient benefit from new immunotherapies, requires multi-disciplinary and highly motivated employees working in a collaborative environment. ImCheck is in the process of developing ambitious programs which build on dynamic exchanges between researchers of the Cancer Research Center of Marseille, clinicians of the Institut Paoli-Calmettes and its worldwide network.

​

Together, we share a wide-range of experience in immunity and cancer as well as in first-in-class drug candidate development, which are aimed at tackling new strategies and strengthening existing cancer treatments.

​

Our journey began in 2015 when the renowned researcher Professor Daniel Olive decided to develop a new "first-in-class" antibody to improve on the first-generation of checkpoint inhibitors in cancer. Today we are one the top peforming start-ups in the biotech industry with a presence in the US.  

​